Teva Gyógyszergyár inaugurates HUF 800 million lab
The local unit of Israeli pharmaceutical company Teva inaugurated a close to HUF 800 million laboratory at its base in Debrecen on Wednesday, according to a report by state news wire MTI.
The lab will double in vitro testing volume in Debrecen, base director Radovan Toman said.
He noted that Teva plowed HUF 450 billion into CAPEX and R&D in Hungary before the latest investment.
Teva's plant in Debrecen produces 7 billion doses of medicine a year.
Teva Gyógyszergyár had revenue of HUF 206 bln last year and the company targets similar turnover this year. About 80% of revenue comes from exports.
ÁKK Sells HUF 82.5 bln of Bonds at Auction, Above Plan
EC Puts Hungary 2024 GDP Growth at 2.4%
HU-rizon Program: HUF 8 bln Funding for International Resear...
Inspiring Women at the Focus of Gourmet Fest
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
